Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Caregiver's opinion sway an older Adult's decision to get the pneumonia vaccine?

NCT ID NCT07809113

Knowledge-focused Sponsor: Endpoints Site Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers in Panama survey adults age 50 and older about pneumococcal disease and the PCV21 vaccine, which protects against pneumonia and other serious infections. One group covers ages 50 to 64; another covers adults 65 and older plus a caregiver who helps them. Each person answers a short questionnaire about vaccine knowledge, trust, barriers, and health information sources. The study gives no vaccine or medicine. It aims to show what shapes vaccine acceptance so health teams can communicate better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the survey maps what drives vaccine acceptance, health teams in Panama and similar countries could write clearer messages that help more older adults get protected against pneumococcal disease.
What could go wrong
This study only asks questions. It cannot prove that any message or caregiver opinion causes someone to get vaccinated, and answers from 600 people may not reflect the whole country.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adults aged 50 years and older in Panama who receive care through public or private health care facilities. Participants will be recruited from urban, semi-urban, and rural settings to reflect the demographic, geographic, and socioeconomic diversity of the adult population in Panama.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Older adults - all cohorts * Age 50 years or older. * Cohort A: 50-64 years. * Cohort B: 65 years or older. * Resident of Panama, including urban, semi-urban, or rural areas. * Has access to medical care through the public or private health care system. * Able and willing to provide signed informed consent. Caregivers - Cohort B only * Age 18 years or older. * Identified as the caregiver of a Cohort B older adult. * Has regular cohabitation or contact with the older adult, defined as at least once per week. * Able and willing to provide signed informed consent. Exclusion Criteria Older adults - all cohorts * Cognitive impairment that prevents the participant from providing informed consent. * Does not speak Spanish and no interpreter is available. Caregivers - Cohort B only \- Professional caregiver with no personal relationship to the older adult.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal immunization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal immunization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CEVAXIN

    Panama City, Provincia de Panamá, Panama

More trials for these conditions

Other studies related to the condition(s) this trial covers.